Services of Alzheimer’s Disease

In 2016 alone, the United States spent $236 billion fighting Alzheimer’s disease and other forms of dementia. More than five million Americans are currently living with Alzheimer’s disease, and it is the sixth-leading cause of death across all ages in the United States.* Stemedica is conducting a Phase IIa Multicenter, Randomized, Single blind, Placebo-controlled, Crossover Study to Assess the Safety, Tolerability, and Preliminary Efficacy of a Single Intravenous Dose of Allogeneic Human Mesenchymal Stem Cells in Subjects with Mild to Moderate Dementia Due to Alzheimer’s Disease.